Literature DB >> 15534088

Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Lutz W Kracht1, Hrvoje Miletic, Susanne Busch, Andreas H Jacobs, Jurgen Voges, Moritz Hoevels, Johannes C Klein, Karl Herholz, Wolf-D Heiss.   

Abstract

PURPOSE: Methyl-[11C]L-methionine ([11C]MET) positron emission tomography (PET) in brain tumors reflects amino acid transport and has been shown to be more sensitive than magnetic resonance imaging in stereotactic biopsy planning. It remains unclear whether the increased [11C]MET uptake is limited to solid tumor tissue or even detects infiltrating tumor parts. EXPERIMENTAL
DESIGN: In 30 patients, a primary or recurrent brain tumor was suspected on magnetic resonance imaging. Patients were investigated with [11C]MET-PET before stereotactic biopsy. The biopsy trajectories were plotted into the [11C]MET-PET images with a newly designed C-based software program. The exact local [11C]MET uptake was determined within rectangular regions of interest of 4 mm in width and length aligned with the biopsy specimen. Individual histologic specimens were rated for the presence of solid tumor tissue, infiltration area, and nontumorous tissue changes.
RESULTS: Receiver operating characteristics analysis demonstrated a sensitivity of 87% and specificity of 89% for the detection of tumor tissue at a threshold of 1.3-fold [11C]MET uptake relative to normal brain tissue. At this threshold, only 13 of 100 tumor positive specimen were false negative mainly in grade 2 astrocytoma. In grade 2 astrocytoma, mean [11C]MET uptake in the infiltration area was significantly higher than in solid tumor tissue (P < 0.003).
CONCLUSIONS: [11C]MET-PET detects solid parts of brain tumors, as well as the infiltration area at high sensitivity and specificity. High [11C]MET uptake in infiltrating tumor of astrocytoma WHO grade 2 reflects high activity in this tumor compartment. Molecular imaging, with [11C]MET, will guide improved management of patients with brain tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534088     DOI: 10.1158/1078-0432.CCR-04-0262

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  91 in total

1.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Authors:  Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-11       Impact factor: 9.236

2.  Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.

Authors:  P Farace; M G Giri; G Meliadò; D Amelio; L Widesott; G K Ricciardi; S Dall'Oglio; A Rizzotti; A Sbarbati; A Beltramello; S Maluta; M Amichetti
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

3.  ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.

Authors:  Kenji Hirata; Shunsuke Terasaka; Tohru Shiga; Naoya Hattori; Keiichi Magota; Hiroyuki Kobayashi; Shigeru Yamaguchi; Kiyohiro Houkin; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

4.  Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.

Authors:  Nobuyuki Kawai; Yukito Maeda; Nobuyuki Kudomi; Keisuke Miyake; Masaki Okada; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-12       Impact factor: 9.236

Review 5.  Microfluidics for positron emission tomography probe development.

Authors:  Ming-Wei Wang; Wei-Yu Lin; Kan Liu; Michael Masterman-Smith; Clifton Kwang-Fu Shen
Journal:  Mol Imaging       Date:  2010-08       Impact factor: 4.488

6.  Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.

Authors:  Nathalie L Albert; Isabel Winkelmann; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Erik Mille; Andrei Todica; Matthias Brendel; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-15       Impact factor: 9.236

7.  Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.

Authors:  Christina I Tsien; Doris Brown; Daniel Normolle; Matthew Schipper; Morand Piert; Larry Junck; Jason Heth; Diana Gomez-Hassan; Randall K Ten Haken; Thomas Chenevert; Yue Cao; Theodore Lawrence
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

8.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

9.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jan H Mehrkens; Jochen Herms; Klaus Seelos; Walter Koch; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

10.  Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma.

Authors:  Michael Lundemann; Per Munck Af Rosenschöld; Aida Muhic; Vibeke A Larsen; Hans S Poulsen; Svend-Aage Engelholm; Flemming L Andersen; Andreas Kjær; Henrik B W Larsson; Ian Law; Adam E Hansen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.